Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a cash flow conversion efficiency ratio of -0.002x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-244.61K) by net assets ($137.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Drugs Made In America Acquisition Corp. worth for the company's overall valuation and market capitalisation.
Drugs Made In America Acquisition Corp. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Drugs Made In America Acquisition Corp. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Drugs Made In America Acquisition Corp. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Drugs Made In America Acquisition Corp. Ordinary Shares ranked by their cash flow conversion efficiency. Explore earnings quality score of Drugs Made In America Acquisition Corp. to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HomeStreet Inc
NASDAQ:HMST
|
-0.024x |
|
Bonduelle S.C.A.
PA:BON
|
0.324x |
|
Shenzhen Ecobeauty Co Ltd
SHE:000010
|
0.103x |
|
Odfjell Technology Ltd
OL:OTL
|
0.083x |
|
PRG Corporation Public Company Limited
BK:PRG
|
-0.025x |
|
Federal Corp
TW:2102
|
-0.009x |
|
Space Asset Acquisition Corp. Class A Ordinary Shares
NASDAQ:SAAQ
|
N/A |
|
Com2uS Corporation
KQ:078340
|
0.009x |
Annual Cash Flow Conversion Efficiency for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2025)
The table below shows the annual cash flow conversion efficiency of Drugs Made In America Acquisition Corp. Ordinary Shares from 2024 to 2025. View Drugs Made In America Acquisition Corp. (DMAA) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $232.64 Million | $-539.19K | -0.002x | -100.00% |
| 2024-12-31 | $-244.85 | $-172.26K | 703.553x | -- |
About Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.